HUTCHMED publishes Phase III ESLIM-01 results in The Lancet Haematology, demonstrating a 48.4% durable response rate for sovleplenib in adult ITP patients.
HUTCHMED announces publication of Phase III ESLIM-01 results in The Lancet Haematology, showcasing a 48.4% durable response rate for their novel, selective oral inhibitor, sovleplenib (HMPL-523), in adult primary immune thrombocytopenia (ITP) patients. These results were also presented at the European Hematology Association (EHA) 2024 Hybrid Congress. Data supports a regulatory submission in China accepted for January 2024.
June 17, 2024
3 Articles